Evidence map›Paper›PMID 34784412›Full record

ArticleInvestigative ophthalmology & visual science2021

Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro.

Revu V L Narayana, Pritikana Jana, Neha Tomar, Varsha Prabhu, Rohini M Nair, Radhika Manukonda, Swathi Kaliki, Sarah E Coupland, Jodi Alexander, Helen Kalirai and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. State of the art in pediatric nanomedicines.Drug delivery and translational research · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Progress of Cancer Stem Cells in Retinoblastoma.Current stem cell research & therapy · 2024
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Revu V L NarayanaSchool of Medical Sciences, University of Hyderabad, Hyderabad, India.
Pritikana JanaDepartment of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, India.
Neha TomarDepartment of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, India.
Varsha PrabhuSchool of Medical Sciences, University of Hyderabad, Hyderabad, India.
Rohini M NairSchool of Medical Sciences, University of Hyderabad, Hyderabad, India.
Radhika ManukondaSchool of Medical Sciences, University of Hyderabad, Hyderabad, India.
Swathi KalikiThe Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, India.
Sarah E CouplandLiverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United Kingdom.
Jodi AlexanderLiverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United Kingdom.
Helen KaliraiLiverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United Kingdom.
Anand K KondapiDepartment of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, India.
Geeta K VemugantiSchool of Medical Sciences, University of Hyderabad, Hyderabad, India.
University of Hyderabad · INUniversity of Liverpool · GBBangor University · GBL V Prasad Eye Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Cancer stem cells (CSCs) are known to contribute to tumor relapses by virtue of their chemoresistance. With the knowledge that nanoformulations can overcome drug resistance, we evaluated the efficacy and cytotoxicity of clinical-grade carboplatin (CPT)- and etoposide (ETP)-loaded lactoferrin nanoparticles (Lf-Nps) on total, CD133-enriched (non-CSC), and CD133-depleted (CSC) populations of retinoblastoma (Rb) Y79 cells. Methods: Physicochemical properties of drug-loaded Lf-Nps were measured with transmission electron microscopy and attenuated total reflectance-Fourier transform infrared. The encapsulation efficiency, uptake, and release of drug-loaded Lf-Nps were measured using high-performance liquid chromatography and a UV-visible spectrophotometer. Cytotoxicity of the standard and drug-loaded Lf-Nps was evaluated by the MTT assay. Results: The mean (SD) size and encapsulation efficiency of Lf-CPT and Lf-ETP were 61.2 (3.94) nm, 60% and 45.15 (5.85) nm, 38%, respectively, and the drug release efficiency was highest at pH 6. The increased drug uptake and lower release of drug-loaded Lf-Nps were observed in CSC and non-CSC populations compared to their standard forms. The relative increase of drug uptake and sustained intracellular retention of the drug-loaded Lf-Nps compared to standard drugs showed an enhanced cytotoxicity up to 50%, especially in Rb Y79 CSCs (IC50: CPT, 230.3; Lf-CPT, 118.2; ETP, 198.1; and Lf-ETP, 129) compared to non-CSCs. Conclusions: Our study documents an increase in drug uptake, retention, and cytotoxicity of Lf-CPT and Lf-ETP on Y79 CSCs and non-CSCs as compared to their standard drugs in vitro. The reversal of chemoresistance in the CSC population by nanoformulation appears promising with the potential to pave the way for improved targeted therapy and better clinical outcomes.

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicBiological AvailabilityCarboplatinChromatography, High Pressure LiquidCulture MediaDrug CarriersDrug Delivery SystemsEtoposideFlow CytometryHumansLactoferrinMicroscopy, ConfocalMicroscopy, Electron, TransmissionNanoparticlesNeoplastic Stem CellsAntineoplastic AgentsAntineoplastic Agents, PhytogenicCarboplatinCulture MediaDrug CarriersEtoposideLactoferrin

Identifiers

PMID34784412
PMCPMC8606840
OpenAlexW3212050803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.